Le Lézard
Classified in: Health
Subject: SVY

The global contract development and manufacturing organization (CDMO) outsourcing market at a CAGR of almost 8% during the forecast period


NEW YORK, Sept. 23, 2019 /PRNewswire/ --

Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market: About this market

Read the full report: https://www.reportlinker.com/p05816300/?utm_source=PRN

Contract development and manufacturing organizations (CDMO) serve companies in the pharmaceutical industry on a contract basis. This CDMO outsourcing market analysis considers sales from small molecules and biologics products. Our analysis also considers the sales of CDMO outsourcing products in APAC, Europe, North America, South America, and MEA. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing focus of vendors on expanding their presence will play a significant role in the small molecules segment to maintain its market position. Also, our global CDMO market report looks at factors such as the growing pharmaceutical industry, increasing demand for one-stop-shop CDMOs, and support of CDMOs in reducing the operational and capital expenses. However, the threat of infringement of intellectual property (IP) rights, serialization issue faced by CDMOs due to multiple production lines and need to comply with regulations may hamper the growth of the CDMO outsourcing industry over the forecast period.

Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market: Overview

Increasing demand for one-stop-shop CDMOs

One-stop-shop CDMOs have high expertise in gaining a competitive edge in the market. They consider various parameters including country-specific requirements, cost efficiency, patient friendliness, and product safety to offer customization of packaging. This enables pharma and biotech firms to safely launch their products in the market. CDMOs not only preserves scarce APIs but also monitors the entire value chain of a product. Such benefits of CDMOs will lead to the expansion of the global contract development and manufacturing organization (CDMO) outsourcing market at a CAGR of almost 8% during the forecast period.

Increasing market consolidation

M&As among CDMOs helps in the expansion of the customer base in new regions and improve the market reach. This inorganic strategy also aids in acquiring technological expertise and develop new innovative products to achieve differentiation from competitors. These developments are increasing consolidation in the market, which is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global CDMO outsourcing market is highly fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading CDMO outsourcing manufacturers, that include Aenova Holding GmbH, Almac Group Ltd., Catalent Inc., FAMAR Health Care Services, FAREVA SA, Lonza Group Ltd., Recipharm AB, Siegfried Holding AG, The Lubrizol Corp., and Thermo Fisher Scientific Inc.

Also, the CDMO outsourcing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Read the full report: https://www.reportlinker.com/p05816300/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 14:04
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) is proud to announce the recipients of the 2024 ADLM and Academy of Diagnostics & Laboratory Medicine Awards. Through this annual awards program, ADLM and its Academy...

at 14:04
Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and...

at 14:00
Help at Home, the leading national provider of innovative, high-quality, home care services, today announced that it is encouraged by the Administration's continued recognition of the value of the home care industry and its critical role in support...

at 13:46
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into distribution agreements for VETIGEL® to be sold through several leading regional distributors of...

at 13:26
Calliditas Therapeutics AB ,  ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com For further information, please contact: Åsa Hillsten, Head of IR & Sustainability,...

at 13:07
Olympus, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today data showing that the use of Narrow Band Imaging (NBI) technology with patients with non-muscle invasive bladder...



News published on and distributed by: